All News

Menin inhibitors for patients with AML have been one of many improvements within the blood cancer space this year, Lee Greenberger of the Leukemia and Lymphoma Society told CURE®.

Today I had lunch with a good friend only to learn his next-door neighbor lost her fight with lung cancer two days ago.

Obtaining molecular genotyping results before first-line treatment resulted in better outcomes for patients with non-small cell lung cancer, an expert explained.

Thomas Silver discusses how a community of support helped a patient when his bone marrow transplant was delayed.

The FDA granted priority review of patritumab deruxtecan for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies.

In a recent study, tarlatamab resulted in improved objective responses and improved survival outcomes in patients with small-cell lung cancer.

We all know that stress is bad.

The Food and Drug Administration has granted an Orphan Drug Designation to SLS009, a CDK9 inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphomas.

A doctor reflected on what it was like treating patients with myeloproliferative neoplasms years ago and how much treatments have improved.

The Gilotrif-Erbitux treatment combination demonstrated antitumor activity in patients with EGFR exon 20 insertion-positive NSCLC, according to a recent study.

Retevmo as a treatment for patients with advanced RET-mutant medullary thyroid cancer “is very exciting,” as treatment options were previously limited, an expert told CURE®.

About four years ago, I wrote a post called "All the Answers" where I discussed the weight of uncertainty after cancer.

The use of telemedicine over in-person oncology visits did not lead to a decrease in advance care planning or an increase in unplanned hospital visits.

An expert explained the benefits of patients with myeloproliferative neoplasms finding a community of people with similar diagnoses.

CURE shares the top stories in breast cancer, which focus on topics like treatment decisions, feelings on awareness months and books focused on breast reconstruction.

Dr. Heather Parsons of Dana-Farber Cancer Institute explains how a liquid biopsy could help patients with breast cancer and their care teams learn vital information.

When the IV was empty, the transplant nurse unhooked me and said “Mr. Katz, Happy Birthday."

Long-term cancer survivors experience diabetes at similar rates as individuals who are cancer-free, but cancer survivors with diabetes face a potentially higher risk of death, researchers have found.

New treatments and ongoing trials are providing more options and better outcomes for patients with myeloproliferative neoplasms, an expert explained.

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.

Last night, my husband asked what I wanted for Christmas.

After being diagnosed with essential thrombocythemia, Marilyn Kay Edwards was not told much about her disease.

Last Christmas, Cathy McQueen didn’t “feel so great” and noticed a strange indent on her right breast — quickly finding out she had a form of breast cancer.

When caring for his wife with myelofibrosis, Ed Bartholemy focused on making her life as fun and positive as possible, despite her limitations.

I heard some bad comments and had scary thoughts after being diagnosed with breast cancer, but the good outweighed the bad.

I had never donated to St. Jude’s Hospital before, even though I’d had cancer twice.

For patients with myeloproliferative neoplasms, it is essential to have an open relationship with oncology nurses, an expert explained.

The Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational adenovirus CAN-2409 plus prodrug Valtrex for the treatment of patients with pancreatic ductal adenocarcinoma.

A phase 2a trial administered the novel drug HT-6184 to its first patient with lower-risk myelodysplastic syndromes.

Patients with Down syndrome and B-cell acute lymphoblastic leukemia tended to have higher rates of treatment-related deaths and poorer overall survival than those without Down syndrome.